Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
8 May 2024
N 14:44 | Template:VSRN diffhist +81 Rithish Nimmagadda talk contribs (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]") |
|
N 14:30 | FRUZAQLA 3 changes history +9,129 [Rithish Nimmagadda (3×)] | |||
|
14:30 (cur | prev) +2 Rithish Nimmagadda talk contribs Tag: Visual edit | ||||
|
14:25 (cur | prev) +35 Rithish Nimmagadda talk contribs | ||||
N |
|
14:10 (cur | prev) +9,092 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...") |
|
N 14:21 | User:Rithish Nimmagadda 3 changes history +362 [Rithish Nimmagadda (3×)] | |||
|
14:21 (cur | prev) −9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
|
14:21 (cur | prev) +9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
N |
|
14:20 (cur | prev) +362 Rithish Nimmagadda talk contribs (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India") |
N 13:32 | Fruzaqla diffhist +49 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}") |
|
04:13 | Zuranolone 2 changes history +5,755 [Alen Antony (2×)] | |||
|
04:13 (cur | prev) +2,528 Alen Antony talk contribs | ||||
|
03:48 (cur | prev) +3,227 Alen Antony talk contribs |
01:58 | User:Edzelco diffhist +22 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
01:55 | Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs |
01:53 | Upload log Edzelco talk contribs uploaded File:LOQTORZI Dosage.png |
7 May 2024
|
N 20:18 | Zuranolone 2 changes history +1,853 [Alen Antony (2×)] | |||
|
20:18 (cur | prev) +1,017 Alen Antony talk contribs | ||||
N |
|
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...") |